About this content We are experts in medium and small-cap markets, we also keep our community up to date with blue-chip companies, commodities and broader investment stories. This is content that excites and engages motivated private investors. About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, inclu ...

Key Takeaways We are already into the second-quarter reporting cycle, and stocks with top-line growth and increasing profit numbers might be popular choices. Moreover, choosing stocks based on a company's efficiency in generating cash flows can be far more rewarding. In this regard, stocks such as Catalyst Pharmaceuticals, Inc. (CPRX) , SunOpta Inc. (STKL) , Gambling.com Group Limited (GAMB) and Orion Group Holdings, Inc. (ORN) are worth buying. This is because even a profit-making company can have a dearth ...

SMM is an asymptomatic intermediate disease state of multiple myeloma where abnormal cells can be detected in the bone marrow. The current standard of care for SMM, even in high-risk cases, is active monitoring (or "Watch and Wait") to track for signs of biochemical progression and/or end-organ damage. This means therapeutic intervention is only offered when the disease progresses. The EC approval is supported by data from the Phase 3 AQUILA study (NCT03301220), evaluating the efficacy and safety of fixed-d ...

Key Takeaways Keytruda accounts for nearly 50% of MRK's pharma revenues, driving growth across cancer indications globally. Early-stage lung cancer and metastatic uptake are fueling strong sales momentum for Keytruda. Heavy reliance on Keytruda poses risks as the 2028 loss of exclusivity draws closer.Merck’s (MRK) primary strength lies in oncology, propelled by its blockbuster PD-L1 inhibitor, Keytruda, which fuels robust growth across various cancer indications worldwide. The drug alone accounts for almo ...

Key Takeaways INTU's new AI agents handle finance, payments, accounting and project management tasks. Enterprise Suite now offers multi-entity views, KPI scorecards and AI-powered forecasting tools. INTU aims to grow in the $89B mid-market by offering ERP-grade intelligence.Intuit Inc. (INTU) unveiled its newest agentic AI enhancements for Intuit Enterprise Suite this week. The update introduces four AI agents — Finance, Payments, Accounting, Project Management — that proactively automate tedious workflow ...

Wednesday, July 23, 2025Pre-market futures are up today, led by foreign auto companies — particularly those in Japan. A new trade agreement was announced that lowers tariffs on Japanese imported autos to +15% from the +27.5% recently slapped on by President Trump. Sweetening the deal is a reported $550 BILLION in investments and loans.Thus, we see this morning Toyota Motors (TM) up +14% in early trading, with Honda Motor Co. (HMC) +11%. Toyota had been saddled with a Zacks Rank #5 (Strong Sell) and Honda wi ...

Key Takeaways PFE's non-oncology Q2 outlook includes growth in Vyndaqel and Nurtec alongside mixed vaccine trends. Primary Care faces IRA pricing pressure on Eliquis and softer international demand for Prevnar. Comirnaty's Q1 rebound raises hopes, while Paxlovid and Abrysvo may reflect lower demand.Pfizer (PFE) is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which account for around 25% of the company’s total revenues. Pfizer’s key oncology drugs ar ...

Key Takeaways SAP's Q2 non-IFRS EPS rose 37% to 1.50 euros, with total revenue up 9% to 9.03B euros Cloud revenue rose 24%, driven by strong ERP Suite growth and robust global client adoption. Non-IFRS operating profit rose 32%, fueled by cost controls and a completed transformation program.SAP SE ((SAP) reported second-quarter 2025 non-IFRS earnings of €1.50 ($1.70) per share, climbing 37% from the year-ago quarter’s levels. The Zacks Consensus Estimate was pegged at $1.63.Driven by robust cloud growth, ...

Scotts Miracle-Gro (SMG) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 30 ...

Dr. Reddy’s Laboratories (RDY) Q1 2026 Earnings Call July 23, 2025 10:00 AM ET Speaker0Good morning, good evening, and a warm welcome to all. Thank you for joining us for doctor Reddy's q one FY twenty six earnings conference call. We truly appreciate your time and participation. Joining us today are members of the leadership team, mister Erez Israeli, our CEO, mister MV Narsimham, our CFO, and the IR team.Earlier today, we released our quarterly financial results. These are now available on our website for ...